Updated on 7 October 2013
"Lilly has successfully replenished and advanced our pipeline to drive growth post-2014, while building a sustainable R&D engine for the long-term," said Mr Jan M Lundberg, executive vice president, science and technology; and president of Lilly Research Laboratories.
He further added, "We've filed for regulatory approval for an unprecedented number of investigational medicines this year with three in diabetes and one in oncology. In the future we expect to maintain a steady state of Phase 3 programs in the mid-to-high single digits, with a robust Phase 1 and Phase 2 pipeline to fill in behind."
Mr Lundberg noted that in the 2013-14 timeframe, the company expects data readouts or pipeline advancements for nine of the assets in late-stage development. These include the three potential launches noted above, the regulatory submissions of necitumumab and the new insulin glargine product, and new data readouts for four other late-stage assets by the end of 2014. Mr Lundberg also said the company anticipates seeing clinical readouts for the vast majority of its phase II assets during this period.